Trinity Biotech plc ADR (TRIB)
NASDAQ: TRIBHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TRIB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.07M
- EPS (TTM)
- -$60.00
- Dividend yield
- None
- 52-week range
- 4.54 – 52.50
- Day range
- 4.54 – 6.24
- Volume / Avg
- 13.79K / 13.54K
- Beta
- —
- Shares outstanding
- 813.13K
- Next earnings
- Dec 22, 2026
52-week range
TRIB stock today
Shares of Trinity Biotech (TRIB) finished higher on Nov 20 at $6.24, a gain of 13.76% or $0.755 per share, versus the S&P 500's 3.70% decline. Shares are 88.1% below their 52-week high of $52.50 and 37.6% above the 52-week low of $4.54, near the bottom of the past year's range. Trinity Biotech has posted a net loss over the last twelve months (EPS of -$60.00), so its P/E ratio is not meaningful.
Trinity Biotech's next earnings report is expected on Dec 22, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Trinity Biotech
Company profileTrinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. John Gillard
- Headquarters
- Bray
- Employees
- 287
- IPO year
- 1992
- Website
- trinitybiotech.com
Financial highlights
Full financialsIn fiscal 2024, Trinity Biotech generated $61.6 million in revenue, up 8.3% from fiscal 2023. Trinity Biotech reported a net loss of $31.8 million, compared with a loss of $24.0 million a year earlier. Gross margin was 34.8% (up from 34.2%) and operating margin -34.4%.
| Fiscal year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $61.55M | $56.83M | $62.52M | $81.15M | $101.98M |
| Growth | +8.31% | -9.10% | -22.96% | -20.43% | +12.77% |
| Net income | $-31.79M | $-24.02M | $-41.01M | $875.00K | $-6.39M |
| EPS (diluted) | — | — | — | — | — |
Earnings
Earnings history- Next report
- Dec 22, 2026
Trinity Biotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BMRABiomerica Inc. | 1.08 | -0.92% | $4.97M | vs TRIB |
| CDIOCardio Diagnostics Holdings Inc. | 1.60 | -3.03% | $4.74M | vs TRIB |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs TRIB |
| QCLSQ/C Technologies Inc. | 0.2784 | -6.01% | $2.40M | vs TRIB |
| VRAXVirax Biolabs Group Limited | 0.3319 | -12.89% | $446.40K | vs TRIB |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs TRIB |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs TRIB |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs TRIB |
Indexes, lists and sector
Trinity Biotech stock FAQ
What is Trinity Biotech's stock price today?
TRIB last traded at $6.24 as of Nov 20, 4:00 PM EST, up 13.76% on the day. Prices are delayed at least 15 minutes.
When is Trinity Biotech's next earnings date?
Trinity Biotech is expected to report earnings on Tuesday, December 22, 2026.
Who is Trinity Biotech's CEO?
Mr. John Gillard is the chief executive officer of Trinity Biotech plc ADR, which has about 287 employees.
What is the TRIB 52-week high?
The 52-week high for TRIB is $52.50 and the 52-week low is $4.54. The stock is currently 88.1% below its high.